Incyte (NASDAQ:INCY) Hit Lower Rating RBC Capital Has $74 Target.

June 27, 2018 - By Andre Harris

Incyte Corporation (NASDAQ:INCY) Corporate Logo

Big Money Sentiment increased to 1.22 in Q1 2018. It has change of 0.16, from 2017Q4’s 1.06. The ratio improved due to Incyte Corporation positioning: 45 sold and 131 reduced. 57 funds took stakes and 157 increased stakes. Investors holded 191.73 million in 2017Q4 but now own 190.28 million shares or 0.76% less.

Wellington Gp Ltd Liability Partnership holds 0.25% or 13.45 million shs in its capital. Royal State Bank Of Canada invested in 965,559 shs or 0.04% of the stock. 4,700 are owned by Quantres Asset Limited. Toronto Dominion Bancorporation holds 0.02% in Incyte Corporation (NASDAQ:INCY) or 94,955 shs. Ny State Teachers Retirement System holds 0.05% of its capital in Incyte Corporation (NASDAQ:INCY) for 248,531 shs. Loring Wolcott And Coolidge Fiduciary Advisors Ltd Liability Partnership Ma stated it has 1,540 shs or 0% of all its holdings. Nordea holds 8,581 shs or 0% of its capital. Emory University has 1.81% invested in Incyte Corporation (NASDAQ:INCY). Gardner Lewis Asset Mngmt Limited Partnership reported 0.24% of its capital in Incyte Corporation (NASDAQ:INCY). Signaturefd Ltd Limited Liability Company owns 104 shs for 0% of their capital. Tower Capital Llc (Trc) has 2,626 shs for 0.02% of their capital. Cap Invsts owns 5.07M shs. Moreover, Point72 Asset Limited Partnership has 0.02% invested in Incyte Corporation (NASDAQ:INCY) for 55,000 shs. Kbc Grp Nv reported 0.01% of its capital in Incyte Corporation (NASDAQ:INCY). Pinebridge Invs Lp has invested 0.05% in Incyte Corporation (NASDAQ:INCY).

Incyte Corporation registered $5.08 million net activity with 1 buying transaction and 4 insider sales since January 5, 2018. $4.99 million worth of stock was sold by SWAIN PAULA J on Monday, April 30. The insider GRYSKA DAVID W sold 1,952 shs worth $167,013. Huber Reid M sold 1,958 shs worth $167,507.

RBC Capital Downgraded Incyte (NASDAQ:INCY)’s Stock Rating to Sector Perform.

On 26 June research analysts at RBC Capital changed Incyte (NASDAQ:INCY)‘s shares rating to Sector Perform from Outperform. INCY has a $74 TP on the stock. That indicates a potential upside move.

Incyte Corporation (NASDAQ:INCY) Ratings Coverage

A total of 16 analysts rate Incyte (NASDAQ:INCY) as follows: 11 “Buy”, 5 “Hold” and 0 “Sell”. Тherefore 69% are bullish. (NASDAQ:INCY) has 23 ratings reports on Jun 27, 2018 according to StockzIntelligence. In Friday, April 6 report Guggenheim downgraded the stock to “Neutral” rating. On Thursday, April 5 Barclays Capital maintained Incyte Corporation (NASDAQ:INCY) with “Overweight” rating. On Thursday, February 15 the stock of Incyte Corporation (NASDAQ:INCY) has “Buy” rating given by BMO Capital Markets. On Tuesday, May 1 the firm earned “Hold” rating by Oppenheimer. On Wednesday, May 30 the stock has “Buy” rating by Piper Jaffray. On Tuesday, January 2 the stock of Incyte Corporation (NASDAQ:INCY) has “Outperform” rating given by RBC Capital Markets. On Tuesday, April 24 JP Morgan maintained the shares of INCY in report with “Overweight” rating. The company rating was maintained by SunTrust on Friday, April 6. In Tuesday, June 26 report RBC Capital Markets downgraded it to “Hold” rating and $7400 target. On Thursday, April 12 the stock of Incyte Corporation (NASDAQ:INCY) earned “Buy” rating by UBS.

INCY is touching $66.43 during the last trading session, after decreased 0.45%.Currently Incyte Corporation is downtrending after 50.56% change in last June 27, 2017. INCY has also 574,982 shares volume. The stock underperformed the S&P 500 by 63.13%.

Incyte Corporation (NASDAQ:INCY) is anticipated to publish earnings on August, 7., according to Faxor. Analysts forecast 0.00 % diference or $-0.06 from the $-0.06 EPS from 2017. Wall Street sees -66.67 % EPS growth as of August, 7.

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States.The firm is valued at $14.08 billion. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.Last it reported negative earnings. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases ; and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs.

For more Incyte Corporation (NASDAQ:INCY) news brought out recently go to: Benzinga.com, Benzinga.com, Seekingalpha.com, Nasdaq.com or 247Wallst.com. The titles are as follows: “Incyte Downgraded As RBC Analyst Awaits More Revenue Visibility” brought out on June 26, 2018, “40 Stocks Moving In Tuesday’s Mid-Day Session” on June 26, 2018, “Incyte’s Jakafi successful in mid-stage study in severe form of GvHD” with a publish date: June 21, 2018, “3 Biotechs With Huge FDA Decisions in June” and the last “Tuesday’s Biggest Winners and Losers in the S&P 500” with publication date: June 26, 2018.

Incyte Corporation (NASDAQ:INCY) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: